Loading...

Potential of liraglutide in the treatment of patients with type 2 diabetes

Liraglutide is a long-acting analog of GLP-1, being developed by Novo Nordisk and currently undergoing regulatory review for the treatment of type 2 diabetes. Upon injection, liraglutide binds non-covalently to albumin, giving it a pharmacokinetic profile suitable for once-daily administration. In c...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Hovedforfatter: Deacon, Carolyn F
Format: Artigo
Sprog:Inglês
Udgivet: Dove Medical Press 2009
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2672437/
https://ncbi.nlm.nih.gov/pubmed/19436648
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!